Advertisement

Loading...

Respiri Limited

RSH.AXASX
Healthcare
Medical - Devices
$0.03
$0.00(0.00%)
Australian Market opens in 17h 57m

Respiri Limited Fundamental Analysis

Respiri Limited (RSH.AX) shows moderate financial fundamentals with a PE ratio of -4.71, profit margin of -15.60%, and ROE of -4.12%. The company generates $0.0B in annual revenue with moderate year-over-year growth of 5.48%.

Key Strengths

PEG Ratio-0.66

Areas of Concern

ROE-4.12%
Operating Margin-16.73%
Cash Position2.36%
We analyze RSH.AX's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1555.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1555.4/100

We analyze RSH.AX's fundamental strength across five key dimensions:

Efficiency Score

Weak

RSH.AX struggles to generate sufficient returns from assets.

ROA > 10%
-1.15%

Valuation Score

Excellent

RSH.AX trades at attractive valuation levels.

PE < 25
-4.71
PEG Ratio < 2
-0.66

Growth Score

Moderate

RSH.AX shows steady but slowing expansion.

Revenue Growth > 5%
5.48%
EPS Growth > 10%
2.78%

Financial Health Score

Excellent

RSH.AX maintains a strong and stable balance sheet.

Debt/Equity < 1
0.49
Current Ratio > 1
1.18

Profitability Score

Weak

RSH.AX struggles to sustain strong margins.

ROE > 15%
-411.64%
Net Margin ≥ 15%
-15.60%
Positive Free Cash Flow
No

Key Financial Metrics

Is RSH.AX Expensive or Cheap?

P/E Ratio

RSH.AX trades at -4.71 times earnings. This suggests potential undervaluation.

-4.71

PEG Ratio

When adjusting for growth, RSH.AX's PEG of -0.66 indicates potential undervaluation.

-0.66

Price to Book

The market values Respiri Limited at 12.74 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.

12.74

EV/EBITDA

Enterprise value stands at -7.35 times EBITDA. This is generally considered low.

-7.35

How Well Does RSH.AX Make Money?

Net Profit Margin

For every $100 in sales, Respiri Limited keeps $-15.60 as profit after all expenses.

-15.60%

Operating Margin

Core operations generate -16.73 in profit for every $100 in revenue, before interest and taxes.

-16.73%

ROE

Management delivers $-4.12 in profit for every $100 of shareholder equity.

-4.12%

ROA

Respiri Limited generates $-1.15 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.15%

Following the Money - Real Cash Generation

Operating Cash Flow

Respiri Limited generates limited operating cash flow of $-10.28M, signaling weaker underlying cash strength.

$-10.28M

Free Cash Flow

Respiri Limited generates weak or negative free cash flow of $-10.28M, restricting financial flexibility.

$-10.28M

FCF Per Share

Each share generates $-0.01 in free cash annually.

$-0.01

FCF Yield

RSH.AX converts -12.78% of its market value into free cash.

-12.78%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-4.71

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

-0.66

vs 25 benchmark

P/B Ratio

Price to book value ratio

12.74

vs 25 benchmark

P/S Ratio

Price to sales ratio

113.77

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

0.49

vs 25 benchmark

Current Ratio

Current assets to current liabilities

1.18

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

-4.12

vs 25 benchmark

ROA

Return on assets percentage

-1.15

vs 25 benchmark

ROCE

Return on capital employed

-2.77

vs 25 benchmark

How RSH.AX Stacks Against Its Sector Peers

MetricRSH.AX ValueSector AveragePerformance
P/E Ratio-4.7128.31 Better (Cheaper)
ROE-411.64%699.00% Weak
Net Margin-1560.30%-130884.00% (disorted) Weak
Debt/Equity0.490.34 Weak (High Leverage)
Current Ratio1.182775.16 Neutral
ROA-115.16%-14469.00% (disorted) Weak

RSH.AX outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Respiri Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

-78.16%

Industry Style: Defensive, Growth, Innovation

Declining

EPS CAGR

58.74%

Industry Style: Defensive, Growth, Innovation

High Growth

FCF CAGR

49.19%

Industry Style: Defensive, Growth, Innovation

High Growth

Fundamental Analysis FAQ